virus removal by simple depth filtration in a two-step ... · affinity step using protein a and two...

1
0 1 2 3 4 5 6 7 8 A B C LRV for MuLV Depth Filters MuLV pH 5.5 pH 7.0 pH 7.0 + 1 N NaCl Virus Removal by Simple Depth Filtration in a Two-Step Downstream Process for mAb Production Alexander Faude 1 , Mario Metzger 1 , Anja Gerster 1 , Marcus Peiker 1 , Sabine Faust 1 , Sybille Ebert 1 , Sophie Winterfeld 2 , Nicole Mang 2 and Dethardt Müller 1 1 Rentschler Biotechnologie GmbH, Laupheim, Germany; Contact: [email protected] 2 3M Deutschland GmbH, Neuss, Germany • mAb purification processes relying on 3 chromatographic steps ensure excellent product quality and patient safety. • Antibody sequences with 2 chromatographic steps enable economic improvement maintaining product quality. • Virus removal by anionic adsorption on depth filters resulted in 2.0 – 5.0 log 10 reduction factors for MuLV and 2.5 – 7.0 log 10 reduction factors for MVM. • Virus removal by depth filtration opens access to a two column step purification platform. Findings DSP Platform for mAb Products Virus Removal by Adsorptive Depth Filtration Figure 2: Production overview for downstream processes with 2 column steps (A: mAb-fusion-protein 3, B: mAb 4). Step yields given in bars, total yields in lines. Assays: HCP (F550, Cygnus); HCD (qPCR, Rentschler). Figure 4: Revised LRV of depth filters for MuLV (Revised LRV = LRV (low salt - high salt). Figure 1: Performance of downstream processes with 3 column steps (A: mAb 1, B: mAb 2). Anion exchange step was needed for virus safety. Step yields given in bars, total yields in lines. Assays: HCP (F550, Cygnus); HCD (qPCR, Rentschler). Figure 3: LRV of depth filters for MuLV. Figure 5: LRV of depth filters for MVM. Generic development platforms for the robust purification of monoclonal antibodies and antibody-related molecules are often driven by facility needs and different strategies of the companies. Most of them include an affinity step using Protein A and two bind/elute or flow through polishing steps. As many platforms were improved over time, one polishing step might be sufficient for adequate process robustness and appropriate product quality of the drug substance. Depth Filtration is a widely used unit operation in state-of-the-art platform purification processes for clearance of precipitates and process-related impurities like HCD and HCP. It is also attractive for being applied as additional virus removal step based on its adsorption capacity caused by its positively charged surface properties. The virus removal potential of depth filters (3M, Meriden, USA) is shown emphasizing its anionic adsorption capability. Log 10 reduction values (LRV) were determined at two process relevant conditions, pH 5.5 and pH 7.0 (”low salt”). For minimizing electrostatic attraction 1 N NaCl (”high salt”) was added at pH 7.0 in MuLV spiked runs to investigate the virus retention by size or other interactions. NaCl addition was omitted for MVM spiked runs due to its small size compared to the filter pores. The contribution of anionic adsorption for additional virus removal by depth filters was shown, resulting in 2.0 – 5.0 log 10 reduction factors for MuLV and 2.5 – 7.0 log 10 reduction factors for MVM. Here, we demonstrated the orthogonal virus removal mechanisms of depth filtration compared to classical virus filtration. The additional virus removal step in the mAb purification sequence increases the overall virus safety of the process and promotes the consideration of a two column step purification platform. Antibody downstream processes based on 3 chromatographic purification steps (Protein A, AEX, CEX, Figure 1) including a charged depth filter ensure excellent quality of the drug substance. Purification sequences with 2 chromatographic steps (Protein A and CEX, Figure 2) including a charged depth filter enable more economic processes with increased product yield maintaining equivalent results in product quality. 1,E+00 1,E+01 1,E+02 1,E+03 1,E+04 1,E+05 1,E+06 1,E+07 0 20 40 60 80 100 HCP (ppm) HCD (ppb) Yield (%) 1,E+00 1,E+01 1,E+02 1,E+03 1,E+04 1,E+05 1,E+06 1,E+07 0 20 40 60 80 100 HCP (ppm) HCD (ppb) Yield (%) 1,E+00 1,E+01 1,E+02 1,E+03 1,E+04 1,E+05 1,E+06 1,E+07 0 20 40 60 80 100 HCP (ppm) HCD (ppb) Yield (%) A A B B 1,E+00 1,E+01 1,E+02 1,E+03 1,E+04 1,E+05 1,E+06 1,E+07 0 20 40 60 80 100 HCP (ppm) HCD (ppb) Yield (%) www.rentschler.de Depth Filters A Zeta Plus™ EXT 60ZA05A B Zeta Plus™ EXT 90ZA05A C Emphaze™ AEX FNW 0 1 2 3 4 5 6 7 8 A B C Revised LRV for MuLV Depth Filters MuLV pH 5.5 pH 7.0 0 1 2 3 4 5 6 7 8 A B C LRV for MVM Depth Filters MVM pH 5.5 pH 7.0

Upload: others

Post on 09-May-2020

6 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Virus Removal by Simple Depth Filtration in a Two-Step ... · affinity step using Protein A and two bind/elute or flow through polishing steps. As many platforms were improved over

0

1

2

3

4

5

6

7

8

A B C

LRV

for M

uLV

Depth Filters

MuLV pH 5.5

pH 7.0

pH 7.0 + 1 N NaCl

Virus Removal by Simple Depth Filtration in aTwo-Step Downstream Process for mAb ProductionAlexander Faude1, Mario Metzger1, Anja Gerster1, Marcus Peiker1, Sabine Faust1, Sybille Ebert1, Sophie Winterfeld2, Nicole Mang2 and Dethardt Müller1

1 Rentschler Biotechnologie GmbH, Laupheim, Germany; Contact: [email protected] 3M Deutschland GmbH, Neuss, Germany

• mAb purification processes relying on 3 chromatographic steps ensure excellent product quality and patient safety.• Antibody sequences with 2 chromatographic steps enable economic improvement maintaining product quality.• Virus removal by anionic adsorption on depth filters resulted in 2.0 – 5.0 log10 reduction factors for MuLV and 2.5 – 7.0 log10 reduction factors for MVM.• Virus removal by depth filtration opens access to a two column step purification platform.

Findings

DSP Platform for mAb Products Virus Removal by Adsorptive Depth Filtration

Figure 2: Production overview for downstream processes with 2 column steps (A: mAb-fusion-protein 3, B: mAb 4). Step yields given in bars, total yields in lines. Assays: HCP (F550, Cygnus); HCD (qPCR, Rentschler).

Figure 4: Revised LRV of depth filters for MuLV (Revised LRV = LRV (low salt - high salt).

Figure 1: Performance of downstream processes with 3 column steps (A: mAb 1, B: mAb 2). Anion exchange step was needed for virus safety. Step yields given in bars, total yields in lines. Assays: HCP (F550, Cygnus); HCD (qPCR, Rentschler).

Figure 3: LRV of depth filters for MuLV.

Figure 5: LRV of depth filters for MVM.

Generic development platforms for the robust purification of monoclonal antibodies and antibody-related molecules are often driven by facility needs and different strategies of the companies. Most of them include an affinity step using Protein A and two bind/elute or flow through polishing steps. As many platforms were improved over time, one polishing step might be sufficient for adequate process robustness and appropriate product quality of the drug substance.

Depth Filtration is a widely used unit operation in state-of-the-art platform purification processes for clearance of precipitates and process- related impurities like HCD and HCP. It is also attractive for being applied as additional virus removal step based on its adsorption capacity caused by its positively charged surface properties.The virus removal potential of depth filters (3M, Meriden, USA) is shown emphasizing its anionic adsorption capability. Log10 reduction values (LRV) were determined at two process relevant conditions, pH 5.5 and pH 7.0 (”low salt”). For minimizing electrostatic attraction 1 N NaCl (”high salt”) was added at pH 7.0 in MuLV spiked runs to investigate the virus retention by size or other interactions. NaCl addition was omitted for MVM spiked runs due to its small size compared to the filter pores.

The contribution of anionic adsorption for additional virus removal by depth filters was shown, resulting in 2.0 – 5.0 log10 reduction factors for MuLV and 2.5 – 7.0 log10 reduction factors for MVM. Here, we demonstrated the orthogonal virus removal mechanisms of depth filtration compared to classical virus filtration. The additional virus removal step in the mAb purification sequence increases the overall virus safety of the process and promotes the consideration of a two column step purification platform.

Antibody downstream processes based on 3 chromatographic purification steps (Protein A, AEX, CEX, Figure 1) including a charged depth filter ensure excellent quality of the drug substance.Purification sequences with 2 chromatographic steps (Protein A and CEX, Figure 2) including a charged depth filter enable more economic processes with increased product yield maintaining equivalent results in product quality.

1,E+00

1,E+01

1,E+02

1,E+03

1,E+04

1,E+05

1,E+06

1,E+07

0

20

40

60

80

100

HCP

(ppm

)HC

D (p

pb)

Yiel

d (%

)

1,E+00

1,E+01

1,E+02

1,E+03

1,E+04

1,E+05

1,E+06

1,E+07

0

20

40

60

80

100

HCP

(ppm

)H

CD (p

pb)

Yiel

d (%

)

1,E+00

1,E+01

1,E+02

1,E+03

1,E+04

1,E+05

1,E+06

1,E+07

0

20

40

60

80

100

HCP

(ppm

)HC

D (p

pb)

Yiel

d (%

)

A

A

B

B

1,E+00

1,E+01

1,E+02

1,E+03

1,E+04

1,E+05

1,E+06

1,E+07

0

20

40

60

80

100

HCP

(ppm

)H

CD (p

pb)

Yiel

d (%

)

www.rentschler.de

Depth Filters

A Zeta Plus™ EXT 60ZA05A

B Zeta Plus™ EXT 90ZA05A

C Emphaze™ AEX FNW

0

1

2

3

4

5

6

7

8

A B C

Revis

ed L

RV fo

r MuL

V

Depth Filters

MuLV pH 5.5

pH 7.0

0

1

2

3

4

5

6

7

8

A B C

LRV

for M

VM

Depth Filters

MVM pH 5.5

pH 7.0